CMS seeks to close Medicare negotiation 'loophole'

1 hour ago

China, rare diseases and affordability: How riders in Congress may shape FDA's user fees

1 hour ago

Takeda builds case around leading orexin program with new Phase 3 data

4 hours ago

Elicio’s KRAS cancer vaccine fails in Phase 2, shares plummet

4 hours ago

Gan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma data

5 hours ago

Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff

6 hours ago

Six leaders working on LGBTQ+ inclusion in biopharma

6 hours ago

Lilly puts its stamp at EHA with Jaypirca combo data in CLL, first clinical data from Ajax buyout

8 hours ago

German biotech nets $50M to advance two depression drugs, including Spravato challenger

14 hours ago

Biopharma’s 2025 industry pay report; Parabilis sets industry record IPO; and more

2 days ago

FDA approves Merck's Welireg-Keytruda combo as adjuvant treatment for kidney cancer

2 days ago

Amgen and the FDA want two different outcomes for Tavneos. What will patients do?

3 days ago

Eli Lilly invests in startup Abridge for clinical trial recruitment

3 days ago

Enliven prices $400M offering; Jazz drug Zepzelca fails confirmatory study

3 days ago

Private jets, wildfire relief and $23,000 internet: The 2025 oddities of biopharma executive pay

3 days ago

WuXi AppTec sues Pentagon in challenge over inclusion on Chinese military list

3 days ago

GSK took advantage of ASCO dip to get discount on Nuvalent

3 days ago

Novo's M&A leader leaves for Forbion; Perrigo CEO's 'personal conduct' issues led to resignation

3 days ago

Sciwind has two Western partners for its obesity drug, but is open to more

3 days ago

The seeming inevitability of rising healthcare costs

4 days ago

Drugmakers are turning to logistics providers as trade disruptions linger, DHL exec says

4 days ago

Summit withdraws $500M offering, citing 'market conditions'

4 days ago

Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy

4 hours ago

Camurus’ second CRL for acromegaly drug; Teva details workforce cuts

4 days ago